AbbVie (ABBV) Peer Comparison
$291.31
$3.07
(1.07%)
As on 06-Nov-2026 16:21EST
Market cap
$509,498 Mln
Revenue (TTM)
$66,014 Mln
P/E Ratio
49.5
P/B Ratio
245.3
Div. Yield
2.4 %
Edit
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
509,498 | 1,206,069 | 655,559 | 362,526 | 305,825 |
Revenue ($ Mln) |
66,014 | 86,462 | 99,335 | 67,302 | 56,306 |
Net Profit ($ Mln) |
10,350.00 | 27,579.70 | 16,095.00 | 2,453.00 | 10,033.05 |
Net Margin (%) |
15.68 | 31.90 | 16.20 | 3.64 | 17.82 |
RoE (%) |
-- | 77.18 | 19.78 | 5.41 | 26.54 |
Price to Earnings |
49.53 | 43.95 | 41.32 | 148.42 | 30.90 |
Price-To-Book |
245.29 | 30.19 | 8.16 | 8.85 | 8.37 |
Income Statement ($ Mln)
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
66,014.00 | 86,462.00 | 99,335.00 | 67,302.00 | 56,305.86 |
|
Cost of Revenue
|
15,677.00 | 14,149.70 | 30,982.00 | 15,512.00 | 14,289.25 |
|
Gross Profit
|
42,956.00 | 54,127.00 | 63,937.00 | 46,731.00 | 41,121.51 |
|
Operating Expenses
|
26,879.00 | 32,481.90 | 42,828.00 | 40,863.00 | 27,682.63 |
|
Operating Profit (EBIT)
|
23,458.00 | 39,830.40 | 25,525.00 | 10,927.00 | 14,333.98 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
12,814.00 | 34,769.20 | 17,737.00 | 4,762.00 | 12,645.68 |
|
Provision for Tax
|
2,466.00 | 7,189.50 | 1,642.00 | 2,313.00 | 2,630.63 |
|
Profit after Tax (Net Income)
|
10,350.00 | 27,579.70 | 16,095.00 | 2,453.00 | 10,033.05 |
|
Minority Interest
|
-6.00 | 0.00 | 0.00 | 4.00 | 18.00 |
|
Consolidated Profit
|
0.00 | 6,636.00 | 5,116.00 | 2,963.00 | 2,409.00 |
Liabilities ($ Mln)
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-5,935.00 | 40,271.00 | 81,529.00 | 44,893.00 | 37,228.00 |
|
Minority Interest
|
-6.00 | 0.00 | 0.00 | 4.00 | 18.00 |
|
Non-Current Liabilities
|
99,361.00 | 60,805.00 | 60,439.00 | 59,026.00 | 47,060.00 |
|
Current Liabilities
|
41,642.00 | 46,996.00 | 55,457.00 | 28,801.00 | 32,525.00 |
|
Total Liabilities
|
133,960.00 | 112,476.00 | 199,210.00 | 136,866.00 | 115,569.20 |
Assets ($ Mln)
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
101,446.00 | 82,809.00 | 141,074.00 | 93,832.00 | 88,402.00 |
|
Current Assets
|
33,669.00 | 65,263.00 | 56,351.00 | 38,941.00 | 28,747.00 |
|
Total Assets
|
133,960.00 | 112,476.00 | 199,210.00 | 136,866.00 | 115,569.20 |
|
Total Debt*
|
70,822.00 | 49,503.00 | 44,651.00 | 53,777.00 | 48,310.00 |
|
Net Current Assets
|
-7,973.00 | 18,267.00 | 894.00 | 10,140.00 | -3,778.00 |
Cashflow ($ Mln)
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
19,030.00 | 16,813.00 | 24,530.00 | 16,472.00 | 19,242.03 |
|
Cash Flow from Investing Activities
|
-6,643.00 | -10,972.00 | -23,588.00 | -13,741.00 | -4,901.98 |
|
Cash from Financing Activities
|
-12,724.00 | -2,213.00 | -5,539.00 | -1,922.00 | -14,943.13 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
6.17 | 35.32 | 22.56 | 19.45 | 17.74 |
|
ROE (%)
|
6,214.71 | 77.18 | 19.78 | 5.41 | 26.54 |
|
ROA (%)
|
5.85 | 15.75 | 6.48 | 1.53 | 6.94 |
|
EBIT Margin (%)
|
26.50 | 49.24 | 18.85 | 9.28 | 25.26 |
|
Net Margin (%)
|
15.68 | 31.90 | 16.20 | 3.64 | 17.82 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
10.68 | 45.51 | 7.80 | 4.79 | -0.12 |
|
EBIT Growth (%)
|
285.20 | 70.32 | -41.80 | -72.96 | -18.88 |
|
Net Profit Growth (%)
|
333.42 | 49.79 | -35.92 | -87.11 | -30.29 |
|
EPS Growth (%)
|
333.38 | 50.65 | -36.38 | -87.04 | -28.45 |
|
Book Value Growth (%)
|
-4,203.16 | 70.28 | 2.00 | -12.72 | -14.48 |
Valuation Ratios
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
95.92 | 46.76 | 18.83 | 14.35 | 18.92 |
|
Price / Book Value
|
-125.57 | 36.37 | 6.19 | 4.98 | 5.77 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
26.61 | 31.56 | 12.97 | 10.54 | 12.68 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-10.53 | 1.17 | 0.44 | 1.11 | 0.99 |
|
Short term debt to equity ratio
|
-1.41 | 0.06 | 0.11 | 0.09 | 0.27 |
|
Current Ratio
|
0.81 | 1.39 | 1.02 | 1.35 | 0.88 |
|
Quick Ratio
|
0.69 | 1.00 | 0.74 | 1.14 | 0.70 |
|
Interest Coverage
|
5.45 | 30.52 | 23.23 | 3.43 | 9.02 |
Operating Efficiency Ratios
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
20.94 | 29.18 | 19.11 | 18.94 | 17.69 |
|
Asset Turnover
|
0.37 | 0.49 | 0.40 | 0.42 | 0.39 |
|
Receivable days
|
70.20 | 93.67 | 70.00 | 64.57 | 63.79 |
|
Inventory Days
|
91.61 | 352.51 | 160.77 | 128.14 | 159.98 |
|
Payable days
|
65.58 | 142.23 | 134.61 | 85.14 | 120.44 |
|
Cash Conversion Cycle
|
96.23 | 303.95 | 96.16 | 107.57 | 103.33 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
